Alveolar Bone LossAlveolar Ridge AugmentationDental Implant
Investigational drug(s) / intervention(s)
concentrated growth factor (CGF) Membrane
concentrated growth factor (CGF) Membrane: This is a third-generation autologous blood concentrate prepared using a dedicated centrifuge system. The process creates a fibrin-rich organic matrix from the patient's own blood, which is then molded into a membrane and packed over the grafted bone to enhance bone density increase and improvement of the surrounding tissue.
Study summary
CGF membranes will be prepared using a swing-lock centrifuge. A full-thickness mucoperiosteal flap will be elevated in a narrow alveolar ridge. Implants will be inserted. Autologous bone chips will be harvested via bone scraping and used for augmentation, CGF membranes will be placed over the grafted area. Suturing of the mucoperiosteal flap. Radiographic evaluation of the bone density and tissue thickness will be performed by CBCT preoperatively, immediate postoperative and after the procedure by 4 months. Clinical evaluation of the tissue thickness using periodontal probe preoperatively, immediate postoperatively and after the procedure by 4 months
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
inclusion criteria:
* A medical history that contraindicates oral surgical treatment such as (uncontrolled/untreated diabetes mellitus, immuno-compromised status, radio or chemotherapy of the oral and maxillofacial region, treatment with oral and/or intravenous bisphosphonates).
* Presence of active or untreated periodontal disease.
* Vertical root fractures involving the buccal aspect.
* Tooth /teeth with horizontal fractures below bone level.
* Tooth /teeth with external or internal resorption.
* Patients with destructive oral habits such as smoking, chewing tobacco, bruxism,etcetera(Chrcanovic et al., 2014).
exclusion criteria: A medical history that contraindicates oral surgical treatment such as (uncontrolled/untreated diabetes mellitus, immuno-compromised status, radio or chemotherapy of the oral and maxillofacial region, treatment with oral and/or intravenous bisphosphonates).
* Presence of active or untreated periodontal disease.
* Vertical root fractures involving the buccal aspect.
* Tooth /teeth with horizontal fractures below bone level.
* Tooth /teeth with external or internal resorption.
* Patients with destructive oral habits such as smoking, chewing tobacco, bruxism, etcetera(Chrcanovic et al., 2014).
Primary outcome measure(s)
tissue biotype — preoperative, immediate postoperative and 4 months after the procedure using periodontal probe to measure gingival thickness
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.